Figure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Martina Chirra(University of Cincinnati), Trisha M. Wise-Draper, Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Jennifer L. Leddon(University of Cincinnati), Farah Abdulla(Caris Life Sciences (United States)), Julie McGrath(Caris Life Sciences (United States)), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Dalia El-Gamal(University of Nebraska Medical Center), Jennifer Maria Johnson, Hira Shaikh, Andrew Elliott, Lova Sun(University of Pennsylvania), Dan P. Zandberg, Anthony N. Karnezis(University of California Davis Medical Center)
Cited by 0
Related Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|521
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341